Shenzhen YHLO Biotech Co's total inventories for the quarter that ended in Mar. 2026 was ¥600 Mil. Shenzhen YHLO Biotech Co's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ¥601 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Shenzhen YHLO Biotech Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ¥-0.33.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Shenzhen YHLO Biotech Co's Days Inventory for the
three
months ended in Mar. 2026 was 365.62.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shenzhen YHLO Biotech Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.25.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shenzhen YHLO Biotech Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.51.
Shenzhen YHLO Biotech Co (SHSE:688575) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Shenzhen YHLO Biotech Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shenzhen YHLO Biotech Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Shenzhen YHLO Biotech Co Total Inventories Related Terms
Shenzhen YHLO Biotech Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Shenzhen YHLO Biotech Co (SHSE:688575) has a Total Inventories of ¥600 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Shenzhen YHLO Biotech Co and its competitors.
Is Shenzhen YHLO Biotech Co's Total Inventories too high?
Shenzhen YHLO Biotech Co's current Total Inventories is ¥600 Mil. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's Total Inventories compare to ABT and SYK?
Shenzhen YHLO Biotech Co's Total Inventories of ¥600 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Shenzhen YHLO Biotech Co and its competitors. Shenzhen YHLO Biotech Co's current Total Inventories is ¥600 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.47, compared to a current price of ¥9.17 — trading 36.6% below its estimated fair value. The current Total Inventories is ¥600 Mil. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current Total Inventories is ¥600 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥9.17 is trading 36.6% below its estimated GF Value™ of ¥14.47.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
Total Inventories: ¥600 Mil
GF Value™: ¥14.47 vs. price of ¥9.17 (36.6% below fair value)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
